Objective-To define further HLA class II gene associations with anticentromere antibody (ACA), a major serum antinuclear antibody in patients with systemic sclerosis (SSc). Methods-HLA class II genes were determined using polymerase chain reaction/ restriction fragment length polymorphisms in 94 Japanese patients with SSc (22 ACA positive and 72 ACA negative) and 50 race matched normal control subjects. Results-Frequency of DQBI*0501 was increased in ACA positive SSc patients compared with ACA negative SSc patients (36% versus 13%; p = 0-02, odds ratio = 4 0, 95% confidence interval 1 1 to 13.9), but the association ofACA with a polar amino acid at position 26 in the DQB1
*1302 alleles were associated with high ACA titres, whereas DRB1*1502 was associated with low ACA titres and a low frequency of centromere protein C (CENP-C) reactivity. Conclusions-These results suggest that the ACA response is associated with multiple HLA class II genes and that ACA positive SSc patients are heterogeneous in terms of immunogenetic background.
(Ann Rheum Dis 1995; 54: [983] [984] [985] [986] [987] It is well known that many autoimmune diseases are associated with certain HLA types.
Systemic sclerosis (or scleroderma) (SSc) is an autoimmune disease characterised by fibrosis of the dermis and internal organs and microvascular damage.' However, previous studies have failed to detect any reproducible HLA associations with SSc,2 presumably because of the heterogeneity of the disease. Recent molecular analyses of genes encoding HIA class II molecules have revealed that HLA class II genes are associated more closely with each SSc related serum antinuclear antibody (ANA) than with the disease itself. For example, the presence of antibody to DNA topoisomerase I (topo I) is associated with DRB1*1502 and DQB1*0601 in Japanese, and broad specificities of DQ3 (DQBl*0301-*0303) in black and white North Americans. 3 4 Anticentromere antibody (ACA) is one of the major SSc related serum ANAs and is detected in about 20% of SSc patients from various ethnic backgrounds.5 ACA occurs in a relatively homogeneous SSc subset having limited cutaneous SSc or the CREST variant (calcinosis, Raynaud's phenomenon, oesophageal dysmotility, sclerodactyly, telangiectasia).' ACA in SSc sera mainly recognise three major centromere constituent proteins (CENP) of molecular weights 16 kDa (CENP-A), 80 kDa (CENP-B), and 140 kDa (CENP-C).6 Increased frequencies of HLA-DR1, -DR4, and -DR8 have been detected in SSc patients with ACA by serological HLA typing.7 8The association of ACA with DR1 and DR4 was confirmed by a recent study using molecular HLA typing.9 Another study using restriction fragment length polymorphism analysis of genomic DNA reported increased frequencies of DRi 1 and DQ7 (DQB1*0301) in patients with the CREST variant, the majority of whom were considered to have ACA.'0 A large study using HLA class II genotyping showed that all the 42 ACA positive SSc patients, compared with 69% of ACA negative SSc patients and 7 1O% of race matched normal control subjects, had at least one DQB 1 allele with a polar amino acid (glycine or tyrosine) at position 26 in the 1 domain, which is shared by DQB1*0501-*0504, *0601, *0301, *0401, and *0402.11 This DQB1 gene association was confirmed by one study analysing HIA class II alleles in ACA positive SSc patients and their relatives,'2 but not by another study. '3 In this study, we analysed the HIA class II gene associations with ACA in Japanese patients with SSc. We also examined HLA associations with ACA titres and immunoreactivities against individual CENP (CENP-A, -B, and -C).
Patients and methods

PATIENTS AND CONTROLS
We studied 94 unrelated Japanese SSc patients who were ' 6 Serum ACA titres were determined by indirect immunofluorescence on chromosomal spreads using twofold serial dilutions of sera ranging from 1:200 to 1:6400. Immunoreactivities against CENP-A, -B, and -C were examined in ACA positive sera by immunoblots using mitotic chromosomes from colcemid arrested HeLa cells as antigens. '7 Briefly, HeLa mitotic chromosomes were resolved on 11% polyacrylamide-sodium dodecyl sulphate gels and transferred onto nitrocellulose filters. The filters were then probed with sera diluted at 1:500 and subsequently with horseradish peroxidase conjugated goat antihuman IgG (Fc-y specific, GIBCO BRL, Grand Island, NY). Immunoreactivities were visualised using a chemiluminescence detection system (DuPont NEN, Boston, MA).
HLA CLASS II ALTLEL TYPING
The HLA-DRB1, -DQB1, and -DPB1 genes were typed using restriction fragment length polymorphisms of polymerase chain reaction amplified genomic DNA as described previously.'8 The numbers of alleles defined by this method are 44 (DRB1), 13 19) . When an association with a particular specificity had been reported previously, the p value was not corrected." The odds ratio (OR) with a 95% confidence interval (95% CI) of the significant differences was calculated, and when one of the four cells of the 2 X 2 tables was 0, Haldane's modification was applied.
Results
Twenty two (23%) of 94 SSc patients were identified as having ACA. Coexistence of other SSc related ANAs in ACA positive SSc patients was infrequent; only one had antibody to Th ribonucleoprotein (RNP). All 22 ACA positive patients were classified as having limited cutaneous SSc. Among 72 ACA negative SSc patients, anti-Ul RNP was detected in 34, anti-topo I in 30, anti-RNA polymerase in four, anti-Th RNP in four, anti-U3 RNP (fibrillarin) in three, and anti-Ku in three. The distribution of SSc related ANAs was similar to that reported in our previous study involving 275 unselected Japanese patients with SSc. ' We could not find any statistically significant differences in HLA-DR allele frequencies when HLA class II gene frequencies in 22 ACA positive patients were compared with those in 72 ACA negative patients and in 50 normal control subjects. However, DR1 (DRBl*0101) was more frequent in ACA positive patients than in ACA negative patients and normal controls (32% versus 13% and 12%, p = 0f051 and 009, respectively). In contrast, there were trends toward lesser frequencies of DR5 (all combined DRB*1l101, *1102, *1201, and *1202) and DR9 (DRBI*0901) in ACA positive patients compared with the other two groups (5% versus 19% and 16%; and 9% versus 24% and 30%, respectively). When DQB1 allele frequencies were compared between ACA positive SSc patients and ACA negative SSc patients or healthy controls (table 1), DQB1*0501 was more frequent in ACA positive patients than in ACA negative patients (p = 0 02). There were trends toward negative associations ofACA with DQB1*0301 and DQB1*0303. The five of six patients possessing DRB1*1502 were included in the low ACA titre group, and the remaining one DRB1*1502 positive patient, whose ACA titre was 3200, had DRB1*1302. Therefore, the frequency of DRB1*1502 in patients with high ACA titres (7%) was significantly lower than that in patients with low ACA titres (68%; p = 0-01, OR = 0-05, 95% CI 0-0 to 0 7). No significant associations between ACA titres and DQB 1 and DPB1 alleles were found.
CENP-A, -B, and -C were recognised by 22 (100%), 22 (100%), and 19 (86%) sera, respectively. All three patients negative for CENP-C reactivity had DRB1*1502, and CENP-C reactivity was detected in only three (50%) of six patients with DRB1*1502 compared with all 16 patients lacking DRB 1* 1502 (p=0-01, OR=0 03, 95% CI 0*0 to 0 7). DQB1*0601 in linkage disequilibrium with DRB1* 1502 is probably not responsible for this negative association with CENP-C reactivity, as sera from all three ACA positive patients possessing DRB1*0803 (another major DRB1 allele that links to DQB1*0601 in Japanese) were reactive with CENP-C.
Discussion
We examined HLA-DRB 1, -DQB 1, and -DPB 1 gene associations with ACA in Japanese patients with SSc. To minimise patient selection bias, we recruited all patients seen in clinic during a period of seven months. As a result, the number of ACA positive SSc patients was relatively small (n = 22); however, we believe that the possible consequent bias does not affect our conclusion, as ANA distribution in the present study was similar to that in unselected SSc patients in our previous study.5 DQA1 was not examined in this study because of strong linkage disequilibrium between DQA1 and DQB1 genes. Our results can be summarised as follows: the presence of ACA was associated with DQB1*0501; a low frequency of CENP-C reactivity was associated with DRB1*1502; high ACA titres were However, the association of ACA with the TRAELDT sequence in DQB1*0501 negative individuals was not confirmed in our study, because the TRAELDT sequence was detected in 13 (93%) of 14 ACA positive SSc patients, but also in all 63 ACA negative SSc patients and 39 (93%) of 42 normal controls, who did not possess DQB1*0501 (data not shown). In common with these recent studies, our present report suggests that ACA responses cannot be explained by the shared amino acid sequences present in the DQB1 genes.
We have shown instead, that high ACA titres are associated with multiple DRB 1 alleles, including DRB1*0101, *0405, and *1302. These DRB 1 alleles do not have shared amino acid sequences in the antigen binding domain. Our recent studies of T cells reactive with topo I revealed that distribution of T cell epitopes on topo I had an association with the nature of the patient's HLA-DR alleles,22 suggesting that each T cell epitope is restricted by distinct HIA-DR alleles. Although to date there are no reports describing T cell responses to centromere proteins, it is possible that several T cell epitopes are present on the centromere antigen complex and that each T cell epitope is restricted by different HLA class II molecules.
